Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;73(6):597-600.
doi: 10.4103/0250-474X.100231.

Febuxostat: a novel agent for management of hyperuricemia in gout

Manisha Bisht  1 , S S Bist
Affiliations

Febuxostat: a novel agent for management of hyperuricemia in gout

Manisha Bisht et al. Indian J Pharm Sci. 2011 Nov.

Abstract

Gout is a metabolic disorder characterized by elevated uric acid levels in the body, associated with painful arthritis, tophi and nephropathy. The most frequently used pharmacologic urate lowering strategies involve reducing urate production with a xanthine oxidase inhibitor and enhancing urinary excretion of uric acid with a uricosuric agent. Urate lowering agents are limited in number, availability and effectiveness. The emergence of a new medication, febuxostat, to lower serum urate levels is welcome as no new drug have been approved since the introduction of allopurinol, in 1964, and the drugs that are available have limitations owing to inefficacy or toxicity. Febuxostat is a novel, nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.

Keywords: Gout; hyperuricemia; xanthine oxidase inhibitor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mechanism of action of febuxostat
See this image and copyright information in PMC

References

    1. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004–7. - PubMed
    1. Kramer HM, Curhan G. The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37–42. - PubMed
    1. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582–7. - PubMed
    1. Becker MA, Jolly M. Metabolic bone and joint disease. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: A textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. pp. 2303–39.
    1. Terkeltaub RA. Gout. N Engl J Med. 2003;349:1647–55. - PubMed

LinkOut - more resources